Crossmark

Emodin, a Potent Anthraquinone Mitigates MPTP-Induced Parkinsons’ Disease Pathology by Regulating Nrf2 and Its Downstream Targets: In Silico and In Vivo Approach

Crossref DOI link: https://doi.org/10.1007/s12035-025-04762-3

Published Online: 2025-02-20

Published Print: 2025-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jahan, Sarwat

Ikram, Muhammad

Siraj, Sami

Ullah, Shakir

Zakria, Muhammad

Ahmad, Nasir
License Information

Text and Data Mining valid from 2025-02-20

Version of Record valid from 2025-02-20
More Information

Article History

Received: 4 September 2024

Accepted: 8 February 2025

First Online: 20 February 2025

Change Date: 25 May 2025

Change Type: Update

Change Details: In the original version of this article, the beta actin in figure 3A is completely identical to 4A in the manuscript. Thus, these were corrected.

Change Date: 27 May 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s12035-025-05091-1

Declarations

:

: The animal maintenance, treatments, behavioral studies, and surgical procedures were carried out according to the Animal Ethics Committee (IACUC) guidelines issued by Khyber Medical University. The experimental methods were carried out according to the approved guidelines, and all experimental protocols were approved by the animal ethics committee (IACUC) of the Khyber Medical University.

: The authors declare no competing interests.

Updates are available Correction dated 2025-05-27

Click to view Correction: https://doi.org/10.1007/s12035-025-05091-1